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Stimulation of a mutant angiotensin type 1A receptor (DRYAAY)
with angiotensin II (Ang II) or of a wild-type receptor with an Ang
II analog ([sarcosine1,Ile4,Ile8]Ang II) fails to activate classical het-
erotrimeric G protein signaling but does lead to recruitment of
-arrestin 2-GFP and activation of extracellular signal-regulated
kinases 1 and 2 (ERK12) (maximum stimulation 50% of wild
type). This G protein-independent activation of mitogen-activated
protein kinase is abolished by depletion of cellular -arrestin 2 but
is unaffected by the PKC inhibitor Ro-31-8425. In parallel, stimu-
lation of the wild-type angiotensin type 1A receptor with Ang II
robustly stimulates ERK12 activation with 60% of the response
blocked by the PKC inhibitor (G protein dependent) and the rest of
the response blocked by depletion of cellular -arrestin 2 by small
interfering RNA (-arrestin dependent). These findings imply the
existence of independent G protein- and -arrestin 2-mediated
pathways leading to ERK12 activation and the existence of dis-
tinct ‘‘active’’ conformations of a seven-membrane-spanning re-
ceptor coupled to each.
S ignaling by seven-membrane-spanning receptors (7MSRs),such as the angiotensin type 1A (AT1A) receptor, is conven-
tionally ascribed to activation of heterotrimeric G proteins.
However, over the past several years an increasing number of
examples have been described in which such receptors signal in
situations in which G protein activation appears to be minimal
or absent (reviewed in ref. 1). In particular, several different
angiotensin receptor mutants and angiotensin peptides, which
are not able to activate G proteins, have been shown to activate
the mitogen-activated protein kinase (MAPK) extracellular
signal-regulated kinases 1 and 2 (ERK12) (2–4). Nonetheless,
the mechanisms mediating such G protein-independent signal-
ing have remained unknown.
One candidate for a molecule that might mediate such sig-
naling is -arrestin. Originally discovered in connection with
their ability, together with G protein-coupled receptor kinases,
to desensitize activated 7MSRs, -arrestin 1 and 2 have been
found recently to act as adaptors in clathrin-mediated endocy-
tosis and as scaffolds for signaling pathways, such as those
leading to activation of MAPKs (5–7). -Arrestin 2 has been
shown to form complexes with the AT1A, NK1 (neurokinin 1),
and V2 (vasopressin 2) receptors, which scaffold and facilitate
activation of the ERK cascade while targeting the activated ERK
to endocytic vesicles in the cytoplasm (8–10). Whether the
-arrestin acts distal to or independent of G proteins in such
signaling is not known. Accordingly, we set out in the present
studies to determine the relationship of G proteins and -
arrestins in ERK activation by the AT1A receptor.
Materials and Methods
Materials. Tissue culture reagents were purchased from Sigma.
The radiolabeled compounds [125I-Tyr4]angiotensin II (Ang II),
guanosine 5-[-[35S]thio]triphosphate ([35S]GTPS), and myo-
[3H]inositol were obtained from NEN. Human Ang II was
purchased from Peninsula Laboratories. [Sar1,Ile4,Ile8]Ang II
(Sar, sarcosine) was synthesized in the Cleveland Clinic core
synthesis facility. Phorbol 12-myristate 13-acetate (PMA) and
Ro-31-8425 were purchased from Calbiochem. Chemically syn-
thesized, double-stranded small interfering RNAs (siRNAs)
corresponding to human -arrestin 2 (bases 148–168 from start
codon; target sequence 5-AAGGACCGCAAAGUGUUU-
GUG-3) and a nonsilencing control (sequence 5-AAGUG-
GACCCUGUAGAUGGCG-3) were purchased from Xeragon
(Germantown, MD) in deprotected and desalted form. GeneSi-
lencer transfection reagents were obtained from Gene Therapy
Systems (San Diego). All other reagents were purchased from
Sigma. The pCDNA3.1 expression plasmid encoding hemagglu-
tinin (HA) epitope-tagged AT1A receptor (pcDNA3.1-HA-
AT1AR) was provided by M. G. Caron (Duke University). The
pCDNA3.1-DRYAAY mutant AT1A receptor construct was
described (11). GFP-tagged -arrestin 2 (-arrestin 2-GFP) was
made by cloning rat -arrestin 2 cDNA in frame in pEGFPN1
(Clontech) between the HindIII and ApaI sites.
Cell Culture and DNA Transfection. Human embryonic kidney
(HEK)-293 cells were grown in Eagle’s minimum essential
medium (MEM) with Earle’s salts supplemented with 10%
(volvol) FBS and a 1:100 dilution of a penicillinstreptomycin
mixture (Sigma). Cells were transiently transfected in 10-cm
dishes with 2 g of pcDNA3.1-HA-AT1AR or pcDNA3.1-DRY
AAY by using FuGENE 6 reagent (Roche Molecular Biochemi-
cals) according to the manufacturer’s instructions.
Inositol Phosphate (IP) Determination. Transiently transfected
HEK-293 cells in 10-cm dishes were plated onto poly-D-lysine-
coated 12-well plates (BD Biosciences Labware). To assay for IP
production, cells were incubated overnight at 37°C in labeling
medium [1 Ci (1 Ci  37 GBq) of myo-[3H]inositol in 0.5 ml of
MEM with 10% FBS per well]. Cells were washed once with PBS
for 30 min at 37°C, washed with PBS containing 20 mM LiCl for
20 min at 37°C, and then treated with agonist for 20 min. Total
IPs were extracted and separated as described (12).
Radioligand Binding. Radioreceptor assays were performed as
described previously by using [125I-Tyr4]Ang II to determine
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cell-surface receptor expression (13). Total protein was deter-
mined by the Bradford reaction and was used to standardize
AT1A receptor expression levels. The receptor expression levels
for wild-type and DRYAAY (Asp-Arg-TyrAla-Ala-Tyr) mu-
tant AT1A receptor are 1.5–2 pmol of receptors per mg of protein
in cells used for IP determination and [35S]GTPS binding assay
and 200–300 fmol of receptors per mg of protein in siRNA-
transfected cells.
[35S]GTPS Binding Assay. Transiently transfected HEK-293 cells
in 10-cm dishes were washed twice in PBS, collected in ice-cold
homogenization buffer (20 mM TrisHCl, pH 7.4100 mM
NaCl1 mM EDTA10 M GDP1 mM PMSFprotease inhib-
itors) and disrupted with a Dounce homogenizer. Crude mem-
branes were prepared by centrifugation at 30,000  g for 30 min
at 4°C. Membranes were resuspended in assay buffer (50 mM
TrisHCl, pH 7.4100 mM NaCl5 mM MgCl21 mM EDTA1
mM DTT10 M GDP). Membranes (15 g of protein per assay
tube) were incubated in 100 pM [35S]GTPS in the presence or
absence of agonist for 1 h at 30°C. Binding was terminated by
addition of 1 ml of 100 M GDPGTP mixture and rapid
filtration over GFB (glass fiber) filters. Filters were washed five
times with ice-cold water and dried, and their radioactivity was
measured with a liquid scintillation counter (Packard).
siRNA Transfection. HEK-293 cells were transfected simulta-
neously with 2 g of pcDNA3.1-HA-AT1AR or pcDNA3.1-
DRYAAY and 20 g of -arrestin 2 siRNA or control siRNA
as described (14).
Confocal Microscopy. HEK-293 cells were transiently transfected
in 10-cm dishes with 2 g of pcDNA3.1-HA-AT1AR or
pcDNA3.1-DRYAAY and 0.5 g of -arrestin 2-GFP. One day
after transfection, cells were split onto collagen-coated 35-mm
plastic dishes with glass bottoms (MatTek, Ashland, MA) and
cultured overnight at 37°C. Cells were then treated with or
without 160 nM Ang II or 30 M [Sar1,Ile4,Ile8]Ang II for 30 min
at 37°C, fixed with PBS containing 5% formaldehyde for 30 min,
and washed three times with PBS. Confocal microscopy was
performed at 100 magnification with a Zeiss LSM-510 laser-
scanning microscope. Images were collected by using 488-nm
excitation and a 515- to 540-nm emission filter.
Preparation of Cellular Extracts and Immunoblotting. Cells were
solubilized in a lysis buffer [50 mM Hepes, pH 7.50.5% Nonidet
P-40250 mM NaCl2 mM EDTA10% (volvol) glycerol1
mM sodium orthovanadate1 mM sodium fluoride1 mM phe-
nylmethylsulfonyl f luoride5 g/ml leupeptin5 g/ml aproti-
nin1 g/ml pepstatin A100 M benzamidine] and then clar-
ified by centrifugation for 10 min at 21,000  g. Equal amounts
of supernatant proteins were separated on 10% Trisglycine
polyacrylamide gels (Invitrogen) and transferred to nitrocellu-
lose membranes for immunoblotting. Phosphorylated ERK12,
total ERK12, and -arrestin 2 were detected by immunoblot-
ting with an anti-phospho-p4442 MAPK antibody (1:3,000; Cell
Signaling Technology, Beverly, MA), an anti-MAPK12
(1:10,000; Upstate Biotechnology, Lake Placid, NY), and a
rabbit polyclonal anti--arrestin 2 antibody (A2CT) (1:5,000),
respectively. Chemiluminescent detection was performed by
using SuperSignal West Pico reagent (Pierce), and phosphory-
lated ERK12 immunoblots were quantified by densitometry
with a Fluor-S MultiImager (Bio-Rad).
Results and Discussion
The highly conserved EDRY (GluAsp-Arg-Tyr) motif in the
second intracellular loop of 7MSRs is important for G protein
coupling. The conserved Arg residue in the rhodopsin EDRY
motif has been shown to interact directly with the G protein to
catalyze GDP release (15), and its mutation causes impaired
signal transduction in many receptors (16, 17). Recently it was
reported that the AT1A receptor mutant DRYAAY (Fig. 1A)
is severely impaired in Gq11-coupling in COS-7 cells (11).
When we transiently expressed this receptor mutant in HEK-293
cells, no detectable inositol 1,4,5-trisphosphate accumulation
was observed (Fig. 2A), confirming that this mutant receptor
lacks functional coupling with Gq11.
Similarly, selected synthetic analogues of Ang II have been
described that can support AT1A receptor internalization with-
out activating IP production through Gq11 (Fig. 1B) (3). Fig.
2A also shows the inability of [Sar1,Ile4,Ile8]Ang II to induce the
coupling of the wild-type AT1A receptor to Gq11 in HEK-293
cells by measuring the production of IP. Because the affinity for
the AT1A receptor is different between Ang II (Kd 1.6 nM) and
[Sar1,Ile4,Ile8]Ang II (Kd  310 nM), the production of IP was
compared at peptide concentrations causing equivalent levels of
receptor occupancy (3). Even at a concentration of 31 M (100
Kd), [Sar1,Ile4,Ile8]Ang II did not induce detectable accumula-
tion of IP, whereas the equivalent concentration of Ang II
maximally activated the production of IP.
The AT1A receptor has been reported to be able to couple to
additional G proteins, such as Gi, in some cell lines (18). To
determine more generally whether [Sar1,Ile4,Ile8]Ang II can
induce the wild-type AT1A receptor to couple to G proteins, and
whether Ang II can induce the DRYAAY mutant receptor to
interact with G proteins, we measured agonist-stimulated
[35S]GTPS binding to cell membranes. Whereas Ang II stim-
ulated a robust increase in [35S]GTPS binding to the AT1A
receptor on cell membranes, no increase in [35S]GTPS bind-
ing was detected even in the presence of 562.5 M
[Sar1,Ile4,Ile8]Ang II (Fig. 2B). Similarly, Ang II did not stim-
ulate [35S]GTPS binding to cell membranes prepared from
Fig. 1. Secondary structure model of the rat AT1A receptor mutant DRYAAY
(A) and sequences of Ang II peptide and its analog [Sar1,Ile4,Ile8]Ang II (B). (A)
Change of DRY to AAY is indicated by arrows. Residues shown in filled circles
are conserved in many 7MSRs. DRYAAY mutant expressed equally well as the
wild-type AT1A receptor in all experiments performed. (B) The Kd values of Ang
II and [Sar1,Ile4,Ile8]Ang II for the wild-type AT1A receptor have been reported
by Holloway et al. (3). The Kd value for the DRYAAY mutant has been
reported to be 2 nM by Gaborik et al. (11). All of these findings have been
verified in this study.
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DRYAAY mutant receptor-transfected cells (Fig. 2B). Con-
sistent with this finding, mutation in the Arg residue of EDRY
motif in the N-formyl peptide receptor has also been shown to
abolish G protein coupling (19). Together, these results dem-
onstrate that the Ang II-bound DRYAAY mutant receptor
lacks coupling to G proteins and that [Sar1,Ile4,Ile8]Ang II is not
able to induce the wild-type AT1A receptor to couple to G
proteins in HEK-293 cells.
To determine whether -arrestin 2 can interact with Ang
II-stimulated DRYAAY receptors and [Sar1,Ile4,Ile8]Ang II-
bound AT1A receptors, we used confocal microscopy to monitor
translocation of -arrestin 2-GFP to receptors on agonist treat-
ment. When -arrestin 2-GFP was coexpressed with the wild-
type AT1A receptor or the DRYAAY mutant receptor, -ar-
restin 2-GFP was distributed uniformly in the cytoplasm of cells
(Fig. 3A). As shown previously, Ang II induced translocation of
-arrestin 2-GFP to endocytic vesicles in cells expressing AT1A
receptors (Fig. 3B) because of a stable interaction between
-arrestin 2-GFP and internalized AT1A receptors (20). Ang
II-induced translocation of -arrestin 2-GFP to endocytic vesi-
cles was also detected in DRYAAY mutant receptor-
transfected cells, suggesting that -arrestin 2 interacts with the
DRYAAY mutant receptor and mediates its internalization on
agonist treatment (Fig. 3C). Similarly, [Sar1,Ile4,Ile8]Ang II also
induced recruitment of -arrestin 2-GFP to endocytic vesicles in
cells expressing wild-type AT1A receptors (Fig. 3D), indicating
that [Sar1,Ile4,Ile8]Ang II-bound wild-type AT1A receptors can
recruit -arrestin 2 in HEK-293 cells. These results are consis-
tent with previous reports that the DRYAAY mutant receptor
undergoes internalization on Ang II stimulation (11) and that
[Sar1,Ile4,Ile8]Ang II can induce AT1A receptor internaliza-
tion (3).
Stimulation of the wild-type AT1A receptor with
[Sar1,Ile4,Ile8]Ang II or the DRYAAY mutant receptor with
Ang II, despite their inability to activate G proteins, led to robust
ERK12 activation, which was 50% of that for the wild-type
receptor stimulated by Ang II (Fig. 4A). The finding that both the
wild-type AT1A receptor stimulated with [Sar1,Ile4,Ile8]Ang II
and the DRYAAY mutant receptor stimulated with Ang II
activated ERK12 in the absence of detectable heterotrimeric G
protein signaling led us to hypothesize that G protein-
independent mechanisms might contribute to AT1A receptor-
induced ERK12 activation. One candidate for mediating G
protein-independent 7MSR signals is -arrestin. -Arrestins
have been shown to bind several signaling proteins, including Src
(21), ERK12 (8, 9, 22, 23), and JNK3 (24) and to recruit them
Fig. 2. [Sar1,Ile4,Ile8]Ang II-bound AT1A receptors and Ang II-bound DRY
AAY mutant receptors fail to induce IP accumulation and [35S]GTPS binding
to cell membranes. (A) HEK-293 cells were transiently transfected with ex-
pression vectors encoding wild-type or DRYAAY AT1A mutant receptors. Cells
were then labeled with myo-[3H]inositol for 20 h, and the dose–response of
Ang II- and [Sar1,Ile4,Ile8]Ang II-induced accumulation of IP was measured.
Each value was then normalized to a percentage of the maximum production
of IP mediated by the wild-type receptor on Ang II treatment in each exper-
iment (n 4). (B) Cell membranes were prepared, and the agonist-stimulated
binding of [35S]GTPS to cell membranes was measured in the presence of the
indicated concentrations [Conc (M)] of agonists. Data are expressed as
percentage increase over the basal values obtained in the absence of agonists
(n  4).
Fig. 3. [Sar1,Ile4,Ile8]Ang II-bound AT1A receptors and Ang II-bound DRY
AAY mutant receptors are able to induce translocation of-arrestin 2-GFP into
endocytic vesicles. HEK-293 cells were transiently transfected with expression
vectors encoding -arrestin 2-GFP and wild-type (B and D) or DRYAAY
mutant AT1A receptors (A and C). Cells were not stimulated (A), stimulated
with 160 nM Ang II (B and C), or stimulated with 30M [Sar1,Ile4,Ile8]Ang II (D)
for 30 min. Cells were fixed with 5% formaldehyde, and the recruitment of
-arrestin 2-GFP was examined by confocal microscopy. The distribution pat-
tern of -arrestin 2-GFP in cells that were not stimulated is the same between
cells expressing the wild-type and DRYAAY mutant AT1A receptors. The
results shown are representative of three experiments.
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Fig. 4. -Arrestin 2 mediates ERK12 activation induced by [Sar1,Ile4,Ile8]Ang II-bound AT1A receptors and the Ang II-bound DRYAAY mutant receptors. (A)
HEK-293 cells were transfected with control siRNA and expression vectors encoding wild-type or DRYAAY-mutant AT1A receptors. Three days after transfection,
cells were cultured in serum-free medium for 4 h and stimulated with 160 nM Ang II or 30 M [Sar1,Ile4,Ile8]Ang II for 5 min. The activation of ERK12 was
determined by immunoblotting with a phospho-ERK12-specific antibody. The levels of phospho-ERK12 were then quantified and normalized to the
phospho-ERK12 signal induced by Ang II-stimulated wild-type AT1A receptors in each experiment. **, P  0.01, compared with the phospho-ERK12 induced
by Ang II-stimulated wild-type AT1A receptors (n 4). (B–G) HEK-293 cells were transfected with control siRNA (CTL siRNA) or -arrestin 2 siRNA and expression
vectors encoding wild-type (WT) (B–E) or DRYAAY-mutant (F and G) AT1A receptors. The activation of ERK12 in cells stimulated with different concentrations
of Ang II (B, C, F, and G) or [Sar1,Ile4,Ile8]Ang II (D and E) was determined as described in A. The amounts of total ERK12 and -arrestin 2 were determined by
stripping the membrane and immunoblotting for total ERK12 and -arrestin 2. The effect of -arrestin 2 siRNA on dose-dependent ERK12 activation induced
by Ang II (C, n  4)- or [Sar1,Ile4,Ile8]Ang II-stimulated wild-type AT1A receptors (E, n  6), or the Ang II-stimulated DRYAAY mutant receptors (G, n  4) was
plotted by normalizing to the maximum phospho-ERK12 signal in each experiment. *, P 0.05; **, P 0.01, compared with the phospho-ERK12 signal in the
corresponding CTL siRNA-transfected cells.
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to 7MSR in an agonist-dependent manner. In the case of the
AT1A receptor, -arrestin 2-bound ERK12 has been shown to
undergo Ang II-stimulated activation and to localize with the
AT1A receptor in endosomal vesicles (8, 9). To assess the
importance of -arrestin 2 in mediating the G protein-
independent activation of ERK12 documented above, we used
the RNA interference technique to down-regulate the expres-
sion of endogenous -arrestin 2 and examined ERK12 activa-
tion by wild-type Ang II, [Sar1,Ile4,Ile8]Ang II, and the DRY
AAY mutant receptor. Down-regulation of -arrestin 2
expression by siRNA transfection decreased the dose-dependent
ERK12 activation induced by Ang II in cells expressing wild-
type AT1A receptors (Fig. 4 B and C), with the maximum
response of ERK12 activation decreasing 50% compared
with that of control siRNA-transfected cells. In contrast, down-
regulation of -arrestin 2 expression by siRNA abolished
ERK12 activation mediated by the wild-type AT1A receptor on
[Sar1,Ile4,Ile8]Ang II treatment (Fig. 4 D and E) or by the
DRYAAY mutant receptor stimulated by Ang II (Fig. 4 F and
G). This finding indicates that the G protein-independent acti-
vation of ERK12 mediated by [Sar1,Ile4,Ile8]Ang II-bound
AT1A receptors or Ang II-bound DRYAAY mutant receptors
is completely dependent on -arrestin 2. Because our -arrestin
2 siRNA did not lead to a decrease in -arrestin 1 expression
levels (data not shown), these results also suggest that -arrestin
2, not -arrestin 1, is the major form of -arrestin mediating Ang
II-induced G protein-independent ERK12 activation.
Because G protein-mediated actions of Ang II are typically
transduced by Gq (leading to generation of IP and diacylglycerol
and activation of PKC), and because PKC has been shown
previously to mediate the Ang II-induced ERK12 activation in
some physiological target tissues (25), we tested the effects of the
PKC inhibitor Ro-31-8425 on ERK12 activation (Fig. 5 A and
B). Activation of ERK12 by wild-type receptor stimulated with
Ang II was inhibited 60% by the PKC inhibitor (Fig. 5A, lanes
3 and 4, Fig. 5B), and the residual activity was virtually elimi-
nated by -arrestin 2 RNA interference (Fig. 5A, lanes 4 and 10,
Fig. 5B). In contrast, ERK12 activation stimulated by
[Sar1,Ile4,Ile8]Ang II was not affected by the PKC inhibitor (Fig.
5A, lanes 5 and 6). As expected, the PKC inhibitor blocked
Erk12 activation by PMA completely (Fig. 5A, lanes 15 and 16).
Our results demonstrate the existence of two parallel inde-
pendent pathways by which ERK can be activated by the AT1A
receptor. One pathway is G protein-dependent and involves PKC
activation, the other is G protein-independent and is mediated
by -arrestin 2. These findings document that -arrestin 2 can act
as a signal transducer entirely independent of G proteins.
However, our results in no way rule out the possibility that under
other circumstances G proteins and -arrestin 2 might act
sequentially. One can imagine several scenarios in which such
sequential rather than parallel activation of the two pathways
might occur. For example, in cases where -arrestin 2 recruit-
ment is triggered by GRK23 (G protein-coupled receptor
kinases 2 and 3)-mediated receptor phosphorylation, the role of
free G in this process would require prior G protein activation
(26, 27). Alternatively, sequential signaling might result when
initial rapid G protein activation of ERK12 is subsequently
terminated (‘‘desensitized’’) by -arrestin 2, which concurrently
initiates the -arrestin 2-dependent phase of ERK12 activation.
It seems likely that ERK12 activation mediated by -arrestin
2 will lead to physiological consequences significantly different
from those achieved by G protein activation. ERK12 activated
by G proteins generally accumulates in the nucleus, where it
phosphorylates and activates various transcription factors (28).
In contrast, ERK12 activated by -arrestin is excluded from the
nucleus and is confined to a cytoplasmic compartment (8) where
it presumably phosphorylates a distinct set of effectors. Consis-
tent with our findings, ERK12 activated by an AT1A mutant
receptor uncoupled from G proteins has been shown to localize
to the cytoplasm and to be unable to induce activation of Elk1
(2). Similarly, stimulation of the DRYAAY mutant receptor
with Ang II does not induce significant Elk1 activation (11).
An important implication of this work is that the receptor can
exist in more than one ‘‘active’’ conformation. Thus, the receptor
conformation induced by [Sar1,Ile4,Il8]Ang II in the wild-type
receptor, or by wild-type Ang II in the DRYAAY mutant
receptor, which is competent to activate ERK12 via -arrestin
2, is not able to activate G proteins. Multiple active conforma-
tions of 7MSRs have been suggested previously, but have been
difficult to document (29, 30). The clear demonstration here of
such functionally distinct active conformations, potentially cou-
pled to distinct signaling pathways, gives credibility and impetus
Fig. 5. Effect of the PKC inhibitor Ro-31-8425 on Ang II- and [Sar1,Ile4,Ile8]Ang II (SII)-induced ERK12 activation. (A) HEK-293 cells were transfected with control
(CTL) siRNA or -arrestin 2 siRNA, and expression vectors encoding wild-type AT1A receptors. Cells were pretreated with or without Ro-31-8425 for 10 min
followed by 5-min stimulation by Ang II or [Sar1,Ile4,Ile8]Ang II. NS, no stimulation. As a control for the effectiveness of the Ro-31-8425, HEK-293 cells were
pretreated with or without Ro-31-8425 for 10 min followed by 5-min stimulation by PMA. The activation of ERK12 was determined by immunoblotting with
a phospho-ERK12-specific antibody (p-Erk12). (B) The effects of -arrestin 2 siRNA and Ro-31-8425 on Ang II-induced ERK12 activation were compared by
normalizing each phospho-ERK12 signal to the response induced by Ang II in non-inhibitor-treated cells transfected with control siRNA (n  4). *, P  0.01,
compared with the ERK12 activation induced by Ang II-stimulated wild-type AT1A receptors; **, P  0.01, compared as indicated.
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to the development of novel therapeutics that might target only
one of several such conformations. Such drugs would likely
demonstrate unique biological actions while displaying more
limited side effects.
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